Precision medicine in Parkinson's disease patients with LRRK2 and GBA risk variants - Let's get even more personal.

ABSTRACT: Parkinson's disease (PD) is characterized by motor deficits and a wide variety of non-motor symptoms. The age of onset, rate of disease progression and the precise profile of motor and non-motor symptoms display considerable individual variation. Neuropathologically, the loss of substantia nigra dopaminergic neurons is a key feature of PD. The vast majority of PD patients exhibit alpha-synuclein aggregates in several brain regions, but there is also great variability in the neuropathology between individuals. While the dopamine replacement therapies can reduce motor symptoms, current therapies do not modify the disease progression. Numerous clinical trials using a wide variety of approaches have failed to achieve disease modification. It has been suggested that the heterogeneity of PD is a

SUBMITTER: von Linstow CU 

PROVIDER: S-EPMC7565766 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature